Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rocca, Andrea
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer	Recruiting	3	400	Europe	Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy	ETOP IBCSG Partners Foundation, Pfizer	Breast Cancer Recurrent	01/25	11/27
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel	Active, not recruiting	2	49	Europe	Atezolizumab,Paclitaxel, Carboplatin	Consorzio Oncotech	Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation	07/24	07/24